Cartilage Regeneration provides
a hyper-personalized therapeutic solution:
Emerging 3D Bioprinting and AI Technology
Application of autologous micronized adipose tissue
and Allograft Hyaline Cartilage (“AHC”) powder
to relief the knee pain and to regenerate the hyaline cartilage

Cartilage Regeneration
Download Brochure
Publication
Contact us
Stage of knee osteoarthritis
HYPER-PERSONALIZED
Cartilage Regeneration

Osteoarthritis disease is dramatically progressed through mid-age. Conventional surgical treatments are high economic burden and not effective to patients.

Hereupon, Cartilage regeneration delivers a cost-effective and hyper-personalized therapeutic solutions to osteoarthritis patients.

Characteristic

As a leading innovative company, ROKIT Healthcare found a solution by emerging 3D bioprinting technology and bio-material inks. Efficacy and safety have been proven through a global clinical study.

Use Autologous MA-ECM
Safety Guarentee
Pain Relief and Cartilage Regeneration
Prevent Total Knee Replacement (TKA) Surgery
One-step Procedure
Easy-to-use & Quick Return to Daily Life
One-time Treatment
Time & Cost Saving
Regeneration Procedure

Harvest
Autologous
Adipose Tissue

Prepare Bio-
Material inks

Print Hyper-
personalized
Cartilage Patch

Implant the
Cartilage Patch

Cartilage
Regeneration

Opening New era of Cartilage Regeneration
niche
Advantages of using Micronized Autologous FAT ECM
  • Minimally invasive to harvest
  • MA-ECM is safer in immune responses
  • MA-ECM contains essential components
    (ex. collagens) that promote regeneration
Advantages of using Allograft Hyaline Cartilage (“AHC”)
  • AHC demonstrates the stiffness of human cartilage
  • AHC introduces regenerating signals to stem cells
  • AHC is Xeno-free with lesser immunity
Similarity Assessment of ROKIT bioscaffold with the normal articular cartilages
Allograft Hyaline Cartilage(“AHC”) vs MA-ECM
  • Based on the L2000 proteomics analysis of AC, AHC, and MA-ECM, AHC held about 82.75% of the growth factors involved in cartilage regeneration.
  • Among these factors, MA-ECM has 31 out of 81 lacking in AHC.
  • Our bioscaffold has 84.30% of growth factors among cartilage regeneration factors, forming regeneration niche to induce homing of stem cells into the damaged area.
Group(s)​ Matched Unmatched Total Matched Percentage(%)
AC vs. AHC 1,655 345 2,000 82.75​
AHC vs. MA-ECM​ 1,593 407 2,000 79.65​
AC vs. AHC + MA-ECM 1,686 314 2,000 84.30​
Pre-clinical result
Proven Cartilage Regenerative Efficacy

From pre-clinical study with Massachusetts General Hospital of Harvard Medical School and Seoul National University, we validated our cartilage regeneration. Recently we already conducted clinical trials from Egypt Assiut University and our clinical paper is about to be published at journal.

Procedure Video
CONTACT INQUIRY

We are always here to help you